The role of the CD40 pathway in the pathogenesis and treatment of cancer.
about
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor.Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-κB activation via a negative feedback loop.Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expressionImmunotherapy for pancreatic cancer - science driving clinical progress.Anti-CD 40 monoclonal antibody.Agonistic CD40 antibodies and cancer therapy.Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis.Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signallingFcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.Evolving pharmacotherapies for the treatment of metastatic melanoma.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Effects of CD40 ligation combined with chemotherapy drugs on human breast cancer cell lines.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion.TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cellsCD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.Development and Validation of a Quasi-Quantitative Bioassay for Neutralizing Antibodies Against CP-870,893.CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.CD40 ligation decreases its protein half-life at the cell surface.A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis.Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth.Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Mechanisms regulating T-cell infiltration and activity in solid tumors.CD40 expression and its prognostic significance in human gastric carcinoma.
P2860
Q33805073-7961EDED-515F-442C-BCC5-0A461A3E4B43Q34384112-F1411BF5-9823-4FF5-A3AD-1A58D40E53E0Q34661963-11654DDC-3EBF-4FC1-80AF-DCA54C28F865Q35130794-70010534-23CB-4784-9075-9CEDF6476F4AQ35165371-E9BD4F3F-1DEC-4151-96BE-9D5CB5E9FAD1Q35546416-DD9143B6-5286-499E-965F-59A46715AA9AQ35800342-056AE7D8-19CD-43C8-901C-50BF5D0A8075Q36133140-DD32EDFC-AB27-4E75-A715-D1FFE53504CDQ36221538-795A0ECD-E0DB-4E46-8353-AD34E981E46AQ36664195-BC54E619-3DF1-45D2-8793-BBD15663B7E4Q36699754-DFDF2561-36BB-41BF-ADFE-0D6376B6C4A9Q37745184-BFB90FF6-F0E1-49F5-9393-CD6386B7E6ECQ38094625-D66E7CB7-6C70-4653-8C2E-AF7C538D749DQ38120749-80EC5F43-481E-4719-AFF7-AFFFF92EDDC1Q38775177-0F0FB429-2DD3-4DB7-BE0C-33A93B3EB897Q39112311-A43B656E-E0FA-4496-9C93-421EB1F6957FQ39189908-096068D7-7275-4B5C-9147-FDEE9B69E82AQ39190801-92EF9682-29D8-4FB7-A00B-7623E6FCC61EQ39295160-B05287E3-5FE1-4EE3-A17C-793EF929BE01Q39613693-EBA741E2-E50A-49BE-B5B0-78626BAF65B9Q39731032-9006D7EA-3384-4A2B-BA82-3710C670C113Q39848254-7EFDD8B8-7CAA-443D-97E4-B348C534F94EQ39923907-5AFA6528-CC6C-4F30-8AE2-76511A13FE8EQ39951749-647531D0-7E5A-4CFD-A28B-EA5DDFC87D86Q40015988-6E8351E7-AA1A-4C60-9A4E-62F66BB0D33DQ41779747-02CC9819-FE61-4DA3-BE78-A4AEA849ECA5Q44124623-4DE127DC-29D1-46E7-9DD3-0A7113ECA35BQ50045161-892839AC-80DF-4780-A7F6-DA2D774BF9ACQ50089395-B1A4FC19-D264-455F-941E-F2FA3248CB83Q53621861-FB23DFDF-42B1-46DD-BD19-116EDF6D0274
P2860
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
@ast
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
@en
type
label
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
@ast
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
@en
prefLabel
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
@ast
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
@en
P1476
The role of the CD40 pathway in the pathogenesis and treatment of cancer
@en
P2093
Lawrence S Young
P304
P356
10.1016/J.COPH.2004.02.008
P577
2004-08-01T00:00:00Z